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Dosing of antibiotics in critically ill patients is a
significant challenge. The increasing number of
patients undergoing extracorporeal membrane
oxygenation further complicates the issue due to
inflammatory activation and to drug sequestration in
the circuit. Since patients receiving extracorporeal
membrane oxygenation commonly face severe
infections, appropriate antibiotic selection and correct
dosing is of paramount importance to improve
survival. Therapeutic drug monitoring (whenever
available) or population pharmacokinetics, based on
readily available clinical and laboratory data, should
help tailor antibiotic dosing to the individual patient.although significant PK changes occur from the resusci-
tation phase to the recovery phase [6].In a recent edition of Critical Care, on behalf of the
Antibiotic, Sedative and Analgesic Pharmacokinetics dur-
ing Extracorporeal Membrane Oxygenation study in-
vestigators, Shekar and colleagues assessed meropenem
pharmacokinetics (PK) in patients receiving extracorpor-
eal membrane oxygenation (ECMO), with or without con-
tinuous renal replacement therapy (CRRT) [1].
Patients on ECMO commonly have infections, reach-
ing rates of more than 15 per 1,000 ECMO days accord-
ing to data pooled from the Extracorporeal Life Support
Organization Registry [2], and these infections are asso-
ciated with increased mortality. There is also increasing
evidence that initial antibiotic appropriateness impacts
the outcome of severe infections. To ensure maximal
bacterial killing, antibiotics should achieve adequate ex-
posure as soon as possible; that is, an adequate concen-
tration during an ideal time, according to the antibiotic’s* Correspondence: joaogpster@gmail.com
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unless otherwise stated.characteristics. Consequently, not only starting an anti-
biotic but also selecting an ideal dose is crucial for thera-
peutic success.
High antibiotic doses are usually needed to achieve
therapeutic concentrations early in the infection course.
This has been shown for β-lactams [3], vancomycin [4]
and aminoglycosides [5], implying the need for higher
than recommended doses. These high doses may also be
necessary to overcome the impact of bacteria resistance,
especially for hospital-acquired infections.
Antibiotics are usually prescribed in a traditional pat-
tern, taking into account only the existence of renal or
liver dysfunction and considering the susceptibility pat-
tern of the microorganism. Moreover, the antibiotic dose
is usually maintained throughout the treatment course,
Ideally, individualized dosing strategies should account
for the altered PK and pathogen susceptibility in each
patient. In order to achieve this goal it is necessary to
understand the full impact of therapeutic interventions
and patient characteristics on antibiotic PK.
Drug dosing in critically ill patients is especially chal-
lenging due to the frequent and hard to predict changes
in PK, especially the increased volume of distribution
and clearance variation [7], secondary to volume resusci-
tation, increased cardiac output and capillary leak. Several
therapeutic procedures are also associated with PK
changes, and both CRRT and ECMO are among the
most challenging. In fact the inflammatory activation
induced by the extracorporeal circulation and exposure
of blood to foreign material and the drug sequestration
in the circuit [8] both contribute to alteration in anti-
biotic concentration and half-life.
ECMO is among the most rapidly increasing support
techniques in intensive care [9], and its use in the
United States has increased more than four times in a
space of only 5 years. Understanding the technique’s im-
pact on antibiotic PK is therefore essential.e BioMed Central Ltd. The licensee has exclusive rights to distribute this article,
ublication. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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http://ccforum.com/content/18/6/695In their study, Shekar and colleagues showed that
the volume of distribution of meropenem is increased
in patients undergoing ECMO (with or without CRRT)
and consequently high initial antibiotic doses were
commonly needed [1]. On the other hand, clearance
was usually low, correlated with CRRT and with creatinine
clearance, so subsequent doses had to be adjusted.
Although conventional dosing was able to achieve a
trough concentration >2 mg/dl in all patients, a higher
target (>8 mg/dl) was only obtained when higher doses
were used [1]. These conclusions were in line with another
recently published study that accessed patients undergoing
CRRT [10]: conventional dosing was not able to achieve
the intended target concentrations in all patients, but
increasing doses also exposed several patients to toxicity.
Therapeutic drug monitoring has been shown to facili-
tate the achievement of adequate antibiotic concentra-
tion [11]. Unfortunately this treatment is only routinely
available for vancomycin and aminoglycosides. Studies
addressing β-lactam antibiotics PK, however, have also
unveiled underdosing and toxic accumulation [12] due
to large interindividual and intraindividual variability,
suggesting the need to tailor the antibiotic dose to the
patient and to adjust it according to PK changes [13,14].
The study by Shekar and colleagues is part of a larger
multicentric effort aimed at the determination of PK of
multiple drugs, namely sedatives, opioids, antibiotics and
antifungals, in ECMO patients [15]. This study is a pains-
taking work of undeniable importance that will culminate
in the determination of evidence-based guidelines for drug
therapy dosage during ECMO.
In conclusion, we can clearly no longer rely on the
‘one size fits all’ paradigm when choosing the antibiotic
dose. Knowledge of antibiotic PK, patient status and im-
mune function, bacteria virulence, susceptibility and in-
oculum, as well as the PK impact of different therapies,
should all contribute to dose selection.
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